Abstract |
The aim of the reported trial was to investigate the safety and efficacy of memantine in mild to moderate vascular dementia (VaD). This was a 28-week, double-blind, parallel, randomized controlled trial of memantine 20 mg daily versus placebo which was conducted in 54 centres in the UK. Memantine is a uncompetitive, moderate affinity N-methyl-D-aspartate receptor antagonist. Patients with a diagnosis of probable VaD and Mini Mental State Examination total scores between 10 and 22 were eligible for inclusion. Primary efficacy parameters were the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-cog) and the Clinical Global Impression of Change (CGI-C). A total of 579 patients were randomized and 548 patients with at least one post-baseline efficacy assessment qualified for the intent-to-treat analysis. At endpoint, memantine was shown to improve cognition relative to placebo in VaD: the change of ADAS-cog from baseline differed by a mean of -1.75 points (95% confidence intervals -3.023 to -0.49) and a median of 2 points between the two groups, while CGI-C ratings showed no significant differences between treatment groups. A total of 77% of all memantine-treated patients experienced adverse event, versus 75% of the placebo-treated patients, dizziness being the most frequent adverse event (11% versus 8%, respectively). Memantine was well tolerated and safe.
|
Authors | G Wilcock, H J Möbius, A Stöffler, MMM 500 group |
Journal | International clinical psychopharmacology
(Int Clin Psychopharmacol)
Vol. 17
Issue 6
Pg. 297-305
(Nov 2002)
ISSN: 0268-1315 [Print] England |
PMID | 12409683
(Publication Type: Clinical Trial, Journal Article, Meta-Analysis, Randomized Controlled Trial)
|
Chemical References |
- Antiparkinson Agents
- Placebos
- Memantine
|
Topics |
- Aged
- Aged, 80 and over
- Antiparkinson Agents
(adverse effects, pharmacology)
- Cognition
- Dementia, Vascular
(drug therapy, pathology)
- Dizziness
(chemically induced)
- Double-Blind Method
- Female
- Humans
- Male
- Memantine
(adverse effects, pharmacology)
- Mental Status Schedule
- Placebos
- Treatment Outcome
|